NEUROPROTECTIVE EFFECTS OF SEMAGLUTIDE AND TIRZEPATIDE DURING THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS
Keywords:
GLP-1, GIP, Neuroinflammation, NeurodegenerationAbstract
Semaglutide, an analog of glucagon-like peptide-1 (GLP-1), and tirzepatide, a dual agonist of GLP-1 and Gastric Inhibitory Peptide (GIP), are effective drugs for the treatment of type 2 diabetes mellitus and weight loss. Studies have demonstrated the presence of receptors for these drugs in the Central Nervous System. Thus, the objective of this article is to conduct an integrative literature review regarding the potential neuroprotective effects of these medications. For this purpose, the PubMed database was used to search for articles published between 2020 and 2025, focusing on the use of semaglutide and tirzepatide in nervous system disorders. Recent studies have shown possible neuroprotective and therapeutic effects of these drugs against neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as well as improvements in cognition and a reduced risk of dementia, with these effects being more prominent in tirzepatide due to its dual-agonist activity. Therefore, these findings highlight the ability of these substances to protect nerve cells, underscoring their potential as therapeutic approaches and the importance of further investigations to confirm their long-term safety and effectiveness.
